Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

Journal of Hepatology

Volumn 44, Issue 2, 2006, Pages 275-282

  Ferenci, Peter ^a   Formann, Elisabeth ^a   Laferl, Hermann ^b   Gschwantler, Michael ^c   Hackl, Franz ^d   Brunner, Harald ^e   Hubmann, Rainer ^f   Datz, Christian ^a   Stauber, Rudolf ^g   Steindl Munda, Petra ^a   Kessler, Harald H ^g   Klingler, Anton ^h   Gangl, Alfred ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

^e GENERAL HOSPITAL LINZ   (Austria)

^f KEPLER UNIVERSITY HOSPITAL   (Austria)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Amantadine; Antiviral therapy; Chronic hepatitis C; Genotype 1

Indexed keywords

AMANTADINE; AMANTADINE SULFATE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SENSITIVITY; DYSPNEA; FEMALE; GENOTYPE; HEARING LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 30344455308     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.09.015     Document Type: Article

References (27)

1. S. Brillanti, F. Levantesi, L. Masi, M. Foli, and L. Bolondi Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C Hepatology 32 2000 630 634
2. A. Mangia, N. Minerva, M. Annese, G. Leandro, M.R. Villani, and R. Santoro A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C Hepatology 33 2001 989 993
3. H. Ullerich, W. Avenhaus, C. Poremba, W. Domschke, and J. Menzel High-dose interferon alpha-2a with ribavirin and amantadine in naive chronic hepatitis C patients - results of a randomized, prospective, pilot study Aliment Pharmacol Ther 16 2002 2107 2114
4. S. Caronia, M.F. Bassendine, R. Barry, P. Mills, N.V. Naoumov, and R. Fox Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study J Hepatol 35 2001 512 516
5. B. Helbling, I. Stamenic, F. Viani, J.J. Gonvers, J.F. Dufour, and J. Reichen Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial Hepatology 35 2002 447 454
6. M. Tabone, C. Laudi, B. Delmastro, A. Biglino, M. Andreoni, and F. Chieppa Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients J Hepatol 35 2001 517 521
7. S. Zeuzem, G. Teuber, U. Naumann, T. Berg, J. Raedle, and S. Hartmann Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C Hepatology 32 2000 835 841
8. A. Mangia, G. Leandro, B. Helbling, E.L. Renner, M. Tabone, and L. Sidoli Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials J Hepatol 40 2004 478 483
9. L.E. Adinolfi, R. Utili, A. Tonziello, and G. Ruggiero Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial Gut 52 2003 701 705
10. T. Berg, B. Kronenberger, H. Hinrichsen, T. Gerlach, P. Buggisch, and E. Herrmann Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial Hepatology 37 2003 1359 1367
11. P. Deltenre, J. Henrion, V. Canva, S. Dharancy, F. Texier, and A. Louvet Evaluation of amantadine in chronic hepatitis C: a meta-analysis J Hepatol 41 2004 462 473
12. S. Engler, C. Flechtenmacher, K.H. Wiedemann, R. Gugler, W. Stremmel, and B. Kallinowski Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection J Viral Hepat 11 2004 60 68
13. R.E. Stauber, H. Hofer, F. Hackl, K. Schutze, C. Datz, and K. Hegenbarth Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine Wien Klin Wochenschr 116 2004 530 535
14. G. Teuber, M. Pascu, T. Berg, M. Lafrenz, J. Pausch, and F. Kullmann Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C J Hepatol 39 2003 606 613
15. P.J. Thuluvath, A. Maheshwari, J. Mehdi, K.D. Fairbanks, L.L. Wu, and L.G. Gelrud Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C Gut 53 2004 130 135
16. C.J. Weegink, R.E. Sentjens, M.G. Beld, M.G. Dijkgraaf, and H.W. Reesink Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study J Viral Hepat 10 2003 174 182
17. Z.M. Younossi, K.D. Mullen, W. Zakko, S. Hodnick, E. Brand, and D.S. Barnes A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy J Hepatol 34 2001 128 133
18. M. Zilly, C. Lingenauber, S. Desch, T. Vath, H. Klinker, and P. Langmann Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin Eur J Med Res 7 2002 149 154
19. W. Jessner, M. Gschwantler, P. Steindl-Munda, H. Hofer, T. Watkins-Riedel, and F. Wrba Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study Lancet 358 2001 1241 1242
20. W. Jessner, R. Stauber, F. Hackl, C. Datz, T. Watkins-Riedel, and H. Hofer Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection J Viral Hepat 10 2003 37 42
21. L.J. Wei The adaptive biased coin design for sequential experiments Ann Statistics 6 1978 92 100
22. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 24 1996 289 293
23. J. Ware, K. Snow, M. Kosinski, and B. Gandek SF-36 health survey: manual and interpretation guide 1993 Boston Boston: The Health Institute, New England Medical
24. L.B. Krupp, N.G. LaRocca, J. Muir-Nash, and A.D. Steinberg The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus Arch Neurol 46 1989 1121 1123
25. D. Hosmer, and S. Lemeshow Applied logistic regression 1989 Wiley New York
26. E. Formann, R. Stauber, D.M. Denk, W. Jessner, G. Zollner, and P. Munda-Steindl Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin Am J Gastroenterol 99 2004 873 877
27. M. Beld, R. Sentjens, S. Rebers, C. Weegink, J. Weel, and C. Sol Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay J Clin Microbiol 40 2002 788 793